1、Breaking Through the Bottlenecks of Traditional Screening | Customized Blind Box Panel Solutions Accelerate Preclinical Decision-Making for Antineoplastic Drugs

Industry Pain Point：Traditional in vitro screening models are single-dimensional, with limited target coverage and low clinical translation rates. Our Blind Box Panel Service enables efficient primary screening of drug candidates through multi-dimensional cell line combinations and high-throughput technologies, reducing late-stage R&D risks.

2、Service Overview

• Positioning:

1. A core link in preclinical screening of antineoplastic drug candidates, covering target validation, primary activity screening, and dose-effect relationship analysis.
2. Industry Pain Points:
3. A single cell line cannot simulate tumor heterogeneity, leading to deviations in clinical efficacy prediction.

• Traditional methods feature low throughput and long cycles, failing to meet the demands of rapidly iterative R&D.
• Solution:
  • Based on a cell bank resource of over 1000 cell lines, we construct cancer-type-oriented or target-oriented customized blind box panels. Combined with a high-throughput detection platform, parallel screening of multiple compounds at multiple concentrations can be completed in 10-14 days, significantly shortening the R&D cycle.

3、Our Services

Technical Solutions by Scenario

Technical Highlights:

• High-throughput detection: Support 96-well plate format, processing more than 100 test substances per day (CTG/CCK-8 method).
• Multi-dimensional data output: Provide dose-effect curves and activity ranking reports of candidate compounds.

4、Technology Platforms and Advantages

1. Technology Platforms:

• Cellular functional platform: MTT/CCK-8/CTG proliferation detection (operating more than 100 cell lines and 100 test substances per day).
• Bioinformatics analysis platform: Integrate STR database and drug target database to support mechanism prediction of active compounds.

2. Infrastructure:

• High-content luminescent proliferation detection system, multi-function microplate reader.
• BSL-2 laboratory (compliant with ISO 14644 cleanliness standards).

3. Differentiated Advantages:

• The only blind box panel supporting a Chinese primary tumor cell bank (more than 100 cell lines), which is more in line with the tumor characteristics of the Asian population.
• Linkage verification with PDX models to improve the accuracy of preclinical prediction.

5、Service Process

1. Demand Communication (1 working day):

• Clarify screening objectives (cancer type/target/compound type) and customize panel solutions.

2. Experiment Execution (5-10 working days):

• Cell culture → drug treatment → high-throughput detection, with real-time sharing of raw data.

3. Data Delivery (3-5 working days):

• Provide GLP-aligned reports (including IC50 dose curves and statistical analysis).

6、Quality Control and Compliance

Executive Standards: Experimental procedures strictly follow GLP specifications (not yet GLP certified but fully process-aligned), and data can be traced back to original records.

Quality Control Measures:

• Dual screening of cell line STR identification (9-locus detection) and mycoplasma.
• Double-blind data review by two researchers, with positive/negative controls set for key experiments.

7、Case Studies

Case 1: Cervical Cancer Targeted Drug Screening for a Top 10 Pharmaceutical Company

• Demand: Primary screening of effective candidates inhibiting EGFR mutations from 200 compounds.
• Solution: Customize a blind box panel (including 5 EGFR-mutant cell lines such as SiHa and C33A).
• Results:

• 5 compounds with high inhibitory activity (IC50<50 nM) were screened out within 14 days.
• The coincidence rate of subsequent CDX model verification exceeded 85%.

8、Cooperation Advantages

• Flexible customization: Support the design of dual-dimensional panels of “cancer type + target” to adapt to different scenarios of small molecule/biological drugs.
• Efficiency improvement: Standardized processes shorten the screening cycle by 50%, and urgent projects can be launched within 72 hours.
• End-to-end support: Enables in vivo efficacy validation using CDX/PDX models and expedites IND filing.

10、FAQ

Q1: Are the sources of cell lines in the blind box panel compliant?

All cell lines have undergone STR identification with clear sources (ATCC/DSMZ/self-established lines), and compliance certificates are provided.

Q2: Can special models (e.g., 3D organoids) be supported?

Not supported for the time being, but 2D-3D combined screening solutions can be provided (subject to separate evaluation).

Q3: Does data delivery meet the audit requirements of multinational pharmaceutical companies?

Raw data packages (including instrument export files and quality control records) are provided, complying with the formal review requirements of EMA/FDA.

11、Laboratory Highlights

Visual Strength

• Equipment: Hamilton liquid handling system (supporting the processing of more than 1,000 samples per day).
• Value: Reduce human errors and ensure data consistency.

View More

12、Contact Us

Tel: +86 18802035152

Email: 3691125803@qq.com